{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:04Z","timestamp":1790666944028,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:00:00Z","timestamp":1340841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> In the setting of allogeneic stem cell transplantation (SCT), infusing natural killer (NK) cells from a major histocompatibility complex (MHC)\u2010mismatched donor can mediate an antileukemic effect. The graft\u2010versus\u2010tumor effect after autologous stem cell transplantation (ASCT) may result in less disease relapse.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> We performed a Phase\u2003I clinical trial to assess the safety and feasibility of infusing distantly processed donor NK\u2010enriched mononuclear cell (NK\u2010MNC) infusions from a MHC haplotype\u2013mismatched (haploidentical) donor to patients who recently underwent ASCT for a hematologic malignancy. On Day 1, peripheral blood MNCs were obtained by steady\u2010state leukapheresis and sent from Boston to the Production Assistance for Cellular Therapies (PACT) facility at the University of Minnesota, where immunomagnetic depletion of CD3 cells was performed on Day\u20032. NK\u2010MNC products were then returned to Boston on Day\u20032 for infusion on Day 3. Toxicity, cellular product characteristics, and logistic events were monitored.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> At a median of 90 days (range, 49\u2010191\u2003days) after ASCT, 13 patients were treated with escalating doses of NK\u2010MNCs per kilogram from 10<jats:sup>5<\/jats:sup> to 2\u2003\u00d7\u200310<jats:sup>7<\/jats:sup>. Adverse effects included Grade\u20032 rigors and muscle aches, but no Grade\u20033 or 4 events and no graft\u2010versus\u2010host disease or marrow suppression. One air courier delay occurred. NK\u2010MNC products were viable with cytotoxic activity after transport.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> CD3\u2010depleted, MHC\u2010mismatched allogeneic NK\u2010MNC infusions can be safely and feasibly administered to patients after ASCT after distant processing and transport, justifying further development of this approach.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03764.x","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T04:51:08Z","timestamp":1340859068000},"page":"412-418","source":"Crossref","is-referenced-by-count":41,"title":["Autologous stem cell transplant recipients tolerate haploidentical related\u2010donor natural killer cell\u2013enriched infusions"],"prefix":"10.1111","volume":"53","author":[{"given":"Hans","family":"Klingemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Grodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Kadidlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie A.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Kewalramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,28]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"PasquiniMC WangZ.Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides.2011. [cited 2012 Jun 7]. Available from: URL:http:\/\/www.cibmtr.org"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1590"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0895"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1829"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0577-x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0342"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90097-S"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1581"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0411-3"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0517-9"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405040"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4011"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA\u2014mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri L","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038687"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.05.007"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-264085"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283051"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065383"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.01.019"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.01145.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.06.016"},{"key":"e_1_2_8_24_2","unstructured":"National Cancer Institute.Cancer therapy evaluation program common terminology criteria for adverse events version 3.0 DCTD NCI NIH DHHS.2003. [cited 2012 Jun 7]. Available from: URL:http:\/\/ctep.cancer.gov"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03695.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02121.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802301872"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024315"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.02.018"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1582"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2355"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02027.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03764.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03764.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:03:55Z","timestamp":1697252635000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03764.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,28]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03764.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03764.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,28]]}}}